Dolsten Mikael 4

What Happened

• Mikael Dolsten, a director of Apellis Pharmaceuticals (APLS), was granted equity awards on February 27, 2026: 14,312 restricted stock units (RSUs) and a derivative equity award for 24,135 shares shown with a $20.96 per-share price (aggregate listed as $505,870). The RSUs are recorded in the filing at $0.00 (award/grant treatment); the derivative award is reported as an option-style grant.

Key Details

• Transaction date: February 27, 2026; Form 4 filed March 3, 2026 (timely — within the two business-day SEC window).
• RSUs: 14,312 shares, reported at $0.00 in the Form 4 (footnote F1).
  • Vesting: RSUs fully vest on the first anniversary of the grant, subject to continued service as a director (or earlier upon his election) (F1).
• Derivative/option award: 24,135 shares, exercise price listed as $20.96 per share; the filing shows $20.96 × 24,135 = $505,870 (F2).
  • Vesting: option award vests one-third per year over three years, subject to continued service (F2).
• Shares owned after transaction: not specified in the provided Form 4 filing.
• Transaction code: A = award/grant. These are compensation grants, not open-market purchases or sales.

Context

• These transactions are grants of compensation (RSUs and options) rather than purchases or sales — such grants are routine for board members and do not by themselves indicate immediate buying or selling in the market.
• The derivative award is a stock option-style grant with multi-year vesting; no exercise or sale of shares occurred per this filing.